BNTX - BioNTech finishes construction of first plasmid DNA manufacturing facility

• BioNTech ( NASDAQ: BNTX ) has completed the building of its first plasmid DNA manufacturing facility in Marburg, Germany.
• Plasmid DNA are the building blocks for the manufacturing of mRNA-based vaccines and therapies, as well as cell therapies.
• The new plant will be used in support of product candidates and commercial products in cancer and infectious diseases.
• The facility actually covers two areas: clinical and commercial plasmid DNA. The clinical side is already running, while the commercial one should be operational by the end of the year .
• See why Seeking Alpha contributor Terry Chrisomalis recently called BioNTech ( BNTX ) a strong buy.

For further details see: